Erectile Dysfunction Drugs Market By Products (Sildenafil, Tadalafil, Udenafil, Avanafil , Others), By Mode of Administration (Oral Medication , Injectable Medication ), By Distribution Channels (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy): Glob
Description
Erectile Dysfunction Drugs Market By Products (Sildenafil, Tadalafil, Udenafil, Avanafil , Others), By Mode of Administration (Oral Medication , Injectable Medication ), By Distribution Channels (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy): Global Opportunity Analysis and Industry Forecast, 2023-2032
The erectile dysfunction drugs market was valued at $2.6 billion in 2022 and is projected to reach $5.1 billion by 2032, growing at a CAGR of 6.5% from 2023 to 2032. Erectile dysfunction (ED) is a common sexual health condition that affects men of all ages. It is defined as the inability to get or maintain an erection sufficient for sexual intercourse. Erectile dysfunction (ED) is often caused by underlying medical conditions such as high blood pressure, diabetes, or heart problems. Other factors that may contribute to erectile dysfunction (ED) include stress, anxiety, depression, nerve damage, certain medications, and lifestyle factors such as smoking and drinking alcohol. Treatment options for erectile dysfunction (ED) include medications, lifestyle changes, and psychological counseling.
The key factor that drives the growth of the erectile dysfunction drugs market are, the increase in the prevalence of chronic disease such as diabetes, hypertension, obesity, and others, and rise in awareness about benefits associated with erectile dysfunction treatment in developing countries such as India and China boost the growth of the market. In addition, the rise in adoption of sedentary lifestyle and surge in the number of erectile dysfunction cases across the globe further boosts the growth of the market. For instance, according to the National Institutes of Health, in 2022, erectile dysfunction (ED) is common condition in the U.S. It affects about 30 million men in the U.S. every year.
However, side effects associated with erectile dysfunction drugs such as blurred vision, nasal congestion, and flushing; and lack of awareness and knowledge about erectile dysfunction among the general population are anticipated to hamper the market growth in the upcoming years. On the contrary, increase in R&D activities in erectile dysfunction treatment, and latest product approvals are expected to provide lucrative opportunities for the growth of the market in the near future.
The erectile dysfunction drugs market is segmented on the basis of product, mode of administration, distribution channel and region. On the basis of product, the market is classified into sildenafil , Avanfil, Tadalafil, udenafil, and others. On the basis of mode of administration, the market is bifurcated into oral medications and injectable medication. On the basis of distribution channel, the market is classified into hospital pharmacy, retail pharmacy and online pharmacy. On the basis of region, the market is analyzed across North America (the U.S., Canada, and Mexico), Europe (Germany, France, the UK, Italy, Spain, and Rest of Europe), Asia-Pacific (China, Japan, Australia, India, South Korea, and Rest of Asia-Pacific), and LAMEA (Brazil, South Africa, Saudi Arabia, and Rest of LAMEA).
Major players profiled in the report are Pfizer Inc., Eli Lilly and Company, Teva Pharmaceutical Industries Ltd., Sanofi, Inc, Sun Pharmaceutical Industries Ltd., Bayer AG, Vivus LLC., Adamed Pharma, Glenmark Pharmaceuticals Limited, and Cipla Ltd.
Key Benefits For Stakeholders
This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the erectile dysfunction drugs market analysis from 2022 to 2032 to identify the prevailing erectile dysfunction drugs market opportunities.
The market research is offered along with information related to key drivers, restraints, and opportunities.
Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
In-depth analysis of the erectile dysfunction drugs market segmentation assists to determine the prevailing market opportunities.
Major countries in each region are mapped according to their revenue contribution to the global market.
Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
The report includes the analysis of the regional as well as global erectile dysfunction drugs market trends, key players, market segments, application areas, and market growth strategies.
Key Market Segments
By Products
Sildenafil
Tadalafil
Udenafil
Avanafil
Others
By Mode of Administration
Oral Medication
Injectable Medication
By Distribution Channels
Hospital Pharmacy
Retail Pharmacy
Online Pharmacy
By Region
North America
U.S.
Canada
Mexico
Europe
Germany
France
UK
Italy
Spain
Rest of Europe
Asia-Pacific
Japan
China
India
Australia
South Korea
Rest of Asia-Pacific
LAMEA
Brazil
Saudi Arabia
South Africa
Rest of LAMEA
Key Market Players
Adamed
Bayer AG
Cipla Ltd
Eli Lilly and Company
Glenmark Pharmaceuticals Limited
Pfizer Inc.
Sanofi
Sun Pharmaceutical Industries Limited
Teva Pharmaceutical Industries Ltd.
Vivus LLC.
Please Note: It will take 7-10 business days to complete the report upon order confirmation.
Table of Contents
417 Pages
- CHAPTER 1: INTRODUCTION
- 1.1. Report description
- 1.2. Key market segments
- 1.3. Key benefits to the stakeholders
- 1.4. Research Methodology
- 1.4.1. Primary research
- 1.4.2. Secondary research
- 1.4.3. Analyst tools and models
- CHAPTER 2: EXECUTIVE SUMMARY
- 2.1. CXO Perspective
- CHAPTER 3: MARKET OVERVIEW
- 3.1. Market definition and scope
- 3.2. Key findings
- 3.2.1. Top impacting factors
- 3.2.2. Top investment pockets
- 3.3. Porter’s five forces analysis
- 3.3.1. Bargaining power of suppliers
- 3.3.2. Bargaining power of buyers
- 3.3.3. Threat of substitutes
- 3.3.4. Threat of new entrants
- 3.3.5. Intensity of rivalry
- 3.4. Market dynamics
- 3.4.1. Drivers
- 3.4.1.1. Rise in prevalence of erectile dysfunction
- 3.4.1.2. Rise in the prevalence of psychological disorders
- 3.4.2. Restraints
- 3.4.2.1. Side effects associated with erectile dysfunction drugs
- 3.4.3. Opportunities
- 3.4.3.1. High growth potential in developing economies
- 3.5. COVID-19 Impact Analysis on the market
- CHAPTER 4: ERECTILE DYSFUNCTION DRUGS MARKET, BY PRODUCTS
- 4.1. Overview
- 4.1.1. Market size and forecast
- 4.2. Sildenafil
- 4.2.1. Key market trends, growth factors and opportunities
- 4.2.2. Market size and forecast, by region
- 4.2.3. Market share analysis by country
- 4.3. Tadalafil
- 4.3.1. Key market trends, growth factors and opportunities
- 4.3.2. Market size and forecast, by region
- 4.3.3. Market share analysis by country
- 4.4. Udenafil
- 4.4.1. Key market trends, growth factors and opportunities
- 4.4.2. Market size and forecast, by region
- 4.4.3. Market share analysis by country
- 4.5. Avanafil
- 4.5.1. Key market trends, growth factors and opportunities
- 4.5.2. Market size and forecast, by region
- 4.5.3. Market share analysis by country
- 4.6. Others
- 4.6.1. Key market trends, growth factors and opportunities
- 4.6.2. Market size and forecast, by region
- 4.6.3. Market share analysis by country
- CHAPTER 5: ERECTILE DYSFUNCTION DRUGS MARKET, BY MODE OF ADMINISTRATION
- 5.1. Overview
- 5.1.1. Market size and forecast
- 5.2. Oral Medication
- 5.2.1. Key market trends, growth factors and opportunities
- 5.2.2. Market size and forecast, by region
- 5.2.3. Market share analysis by country
- 5.3. Injectable Medication
- 5.3.1. Key market trends, growth factors and opportunities
- 5.3.2. Market size and forecast, by region
- 5.3.3. Market share analysis by country
- CHAPTER 6: ERECTILE DYSFUNCTION DRUGS MARKET, BY DISTRIBUTION CHANNELS
- 6.1. Overview
- 6.1.1. Market size and forecast
- 6.2. Hospital Pharmacy
- 6.2.1. Key market trends, growth factors and opportunities
- 6.2.2. Market size and forecast, by region
- 6.2.3. Market share analysis by country
- 6.3. Retail Pharmacy
- 6.3.1. Key market trends, growth factors and opportunities
- 6.3.2. Market size and forecast, by region
- 6.3.3. Market share analysis by country
- 6.4. Online Pharmacy
- 6.4.1. Key market trends, growth factors and opportunities
- 6.4.2. Market size and forecast, by region
- 6.4.3. Market share analysis by country
- CHAPTER 7: ERECTILE DYSFUNCTION DRUGS MARKET, BY REGION
- 7.1. Overview
- 7.1.1. Market size and forecast By Region
- 7.2. North America
- 7.2.1. Key trends and opportunities
- 7.2.2. Market size and forecast, by Products
- 7.2.3. Market size and forecast, by Mode of Administration
- 7.2.4. Market size and forecast, by Distribution Channels
- 7.2.5. Market size and forecast, by country
- 7.2.5.1. U.S.
- 7.2.5.1.1. Key market trends, growth factors and opportunities
- 7.2.5.1.2. Market size and forecast, by Products
- 7.2.5.1.3. Market size and forecast, by Mode of Administration
- 7.2.5.1.4. Market size and forecast, by Distribution Channels
- 7.2.5.2. Canada
- 7.2.5.2.1. Key market trends, growth factors and opportunities
- 7.2.5.2.2. Market size and forecast, by Products
- 7.2.5.2.3. Market size and forecast, by Mode of Administration
- 7.2.5.2.4. Market size and forecast, by Distribution Channels
- 7.2.5.3. Mexico
- 7.2.5.3.1. Key market trends, growth factors and opportunities
- 7.2.5.3.2. Market size and forecast, by Products
- 7.2.5.3.3. Market size and forecast, by Mode of Administration
- 7.2.5.3.4. Market size and forecast, by Distribution Channels
- 7.3. Europe
- 7.3.1. Key trends and opportunities
- 7.3.2. Market size and forecast, by Products
- 7.3.3. Market size and forecast, by Mode of Administration
- 7.3.4. Market size and forecast, by Distribution Channels
- 7.3.5. Market size and forecast, by country
- 7.3.5.1. Germany
- 7.3.5.1.1. Key market trends, growth factors and opportunities
- 7.3.5.1.2. Market size and forecast, by Products
- 7.3.5.1.3. Market size and forecast, by Mode of Administration
- 7.3.5.1.4. Market size and forecast, by Distribution Channels
- 7.3.5.2. France
- 7.3.5.2.1. Key market trends, growth factors and opportunities
- 7.3.5.2.2. Market size and forecast, by Products
- 7.3.5.2.3. Market size and forecast, by Mode of Administration
- 7.3.5.2.4. Market size and forecast, by Distribution Channels
- 7.3.5.3. UK
- 7.3.5.3.1. Key market trends, growth factors and opportunities
- 7.3.5.3.2. Market size and forecast, by Products
- 7.3.5.3.3. Market size and forecast, by Mode of Administration
- 7.3.5.3.4. Market size and forecast, by Distribution Channels
- 7.3.5.4. Italy
- 7.3.5.4.1. Key market trends, growth factors and opportunities
- 7.3.5.4.2. Market size and forecast, by Products
- 7.3.5.4.3. Market size and forecast, by Mode of Administration
- 7.3.5.4.4. Market size and forecast, by Distribution Channels
- 7.3.5.5. Spain
- 7.3.5.5.1. Key market trends, growth factors and opportunities
- 7.3.5.5.2. Market size and forecast, by Products
- 7.3.5.5.3. Market size and forecast, by Mode of Administration
- 7.3.5.5.4. Market size and forecast, by Distribution Channels
- 7.3.5.6. Rest of Europe
- 7.3.5.6.1. Key market trends, growth factors and opportunities
- 7.3.5.6.2. Market size and forecast, by Products
- 7.3.5.6.3. Market size and forecast, by Mode of Administration
- 7.3.5.6.4. Market size and forecast, by Distribution Channels
- 7.4. Asia-Pacific
- 7.4.1. Key trends and opportunities
- 7.4.2. Market size and forecast, by Products
- 7.4.3. Market size and forecast, by Mode of Administration
- 7.4.4. Market size and forecast, by Distribution Channels
- 7.4.5. Market size and forecast, by country
- 7.4.5.1. Japan
- 7.4.5.1.1. Key market trends, growth factors and opportunities
- 7.4.5.1.2. Market size and forecast, by Products
- 7.4.5.1.3. Market size and forecast, by Mode of Administration
- 7.4.5.1.4. Market size and forecast, by Distribution Channels
- 7.4.5.2. China
- 7.4.5.2.1. Key market trends, growth factors and opportunities
- 7.4.5.2.2. Market size and forecast, by Products
- 7.4.5.2.3. Market size and forecast, by Mode of Administration
- 7.4.5.2.4. Market size and forecast, by Distribution Channels
- 7.4.5.3. India
- 7.4.5.3.1. Key market trends, growth factors and opportunities
- 7.4.5.3.2. Market size and forecast, by Products
- 7.4.5.3.3. Market size and forecast, by Mode of Administration
- 7.4.5.3.4. Market size and forecast, by Distribution Channels
- 7.4.5.4. Australia
- 7.4.5.4.1. Key market trends, growth factors and opportunities
- 7.4.5.4.2. Market size and forecast, by Products
- 7.4.5.4.3. Market size and forecast, by Mode of Administration
- 7.4.5.4.4. Market size and forecast, by Distribution Channels
- 7.4.5.5. South Korea
- 7.4.5.5.1. Key market trends, growth factors and opportunities
- 7.4.5.5.2. Market size and forecast, by Products
- 7.4.5.5.3. Market size and forecast, by Mode of Administration
- 7.4.5.5.4. Market size and forecast, by Distribution Channels
- 7.4.5.6. Rest of Asia-Pacific
- 7.4.5.6.1. Key market trends, growth factors and opportunities
- 7.4.5.6.2. Market size and forecast, by Products
- 7.4.5.6.3. Market size and forecast, by Mode of Administration
- 7.4.5.6.4. Market size and forecast, by Distribution Channels
- 7.5. LAMEA
- 7.5.1. Key trends and opportunities
- 7.5.2. Market size and forecast, by Products
- 7.5.3. Market size and forecast, by Mode of Administration
- 7.5.4. Market size and forecast, by Distribution Channels
- 7.5.5. Market size and forecast, by country
- 7.5.5.1. Brazil
- 7.5.5.1.1. Key market trends, growth factors and opportunities
- 7.5.5.1.2. Market size and forecast, by Products
- 7.5.5.1.3. Market size and forecast, by Mode of Administration
- 7.5.5.1.4. Market size and forecast, by Distribution Channels
- 7.5.5.2. Saudi Arabia
- 7.5.5.2.1. Key market trends, growth factors and opportunities
- 7.5.5.2.2. Market size and forecast, by Products
- 7.5.5.2.3. Market size and forecast, by Mode of Administration
- 7.5.5.2.4. Market size and forecast, by Distribution Channels
- 7.5.5.3. South Africa
- 7.5.5.3.1. Key market trends, growth factors and opportunities
- 7.5.5.3.2. Market size and forecast, by Products
- 7.5.5.3.3. Market size and forecast, by Mode of Administration
- 7.5.5.3.4. Market size and forecast, by Distribution Channels
- 7.5.5.4. Rest of LAMEA
- 7.5.5.4.1. Key market trends, growth factors and opportunities
- 7.5.5.4.2. Market size and forecast, by Products
- 7.5.5.4.3. Market size and forecast, by Mode of Administration
- 7.5.5.4.4. Market size and forecast, by Distribution Channels
- CHAPTER 8: COMPETITIVE LANDSCAPE
- 8.1. Introduction
- 8.2. Top winning strategies
- 8.3. Product Mapping of Top 10 Player
- 8.4. Competitive Dashboard
- 8.5. Competitive Heatmap
- 8.6. Top player positioning, 2022
- CHAPTER 9: COMPANY PROFILES
- 9.1. Pfizer Inc.
- 9.1.1. Company overview
- 9.1.2. Key Executives
- 9.1.3. Company snapshot
- 9.1.4. Operating business segments
- 9.1.5. Product portfolio
- 9.1.6. Business performance
- 9.1.7. Key strategic moves and developments
- 9.2. Eli Lilly and Company
- 9.2.1. Company overview
- 9.2.2. Key Executives
- 9.2.3. Company snapshot
- 9.2.4. Operating business segments
- 9.2.5. Product portfolio
- 9.2.6. Business performance
- 9.3. Teva Pharmaceutical Industries Ltd.
- 9.3.1. Company overview
- 9.3.2. Key Executives
- 9.3.3. Company snapshot
- 9.3.4. Operating business segments
- 9.3.5. Product portfolio
- 9.3.6. Business performance
- 9.4. Sanofi
- 9.4.1. Company overview
- 9.4.2. Key Executives
- 9.4.3. Company snapshot
- 9.4.4. Operating business segments
- 9.4.5. Product portfolio
- 9.4.6. Business performance
- 9.5. Bayer AG
- 9.5.1. Company overview
- 9.5.2. Key Executives
- 9.5.3. Company snapshot
- 9.5.4. Operating business segments
- 9.5.5. Product portfolio
- 9.5.6. Business performance
- 9.6. Vivus LLC.
- 9.6.1. Company overview
- 9.6.2. Key Executives
- 9.6.3. Company snapshot
- 9.6.4. Operating business segments
- 9.6.5. Product portfolio
- 9.7. Adamed
- 9.7.1. Company overview
- 9.7.2. Key Executives
- 9.7.3. Company snapshot
- 9.7.4. Operating business segments
- 9.7.5. Product portfolio
- 9.8. Glenmark Pharmaceuticals Limited
- 9.8.1. Company overview
- 9.8.2. Key Executives
- 9.8.3. Company snapshot
- 9.8.4. Operating business segments
- 9.8.5. Product portfolio
- 9.8.6. Business performance
- 9.8.7. Key strategic moves and developments
- 9.9. Cipla Ltd
- 9.9.1. Company overview
- 9.9.2. Key Executives
- 9.9.3. Company snapshot
- 9.9.4. Operating business segments
- 9.9.5. Product portfolio
- 9.9.6. Business performance
- 9.10. Sun Pharmaceutical Industries Limited
- 9.10.1. Company overview
- 9.10.2. Key Executives
- 9.10.3. Company snapshot
- 9.10.4. Operating business segments
- 9.10.5. Product portfolio
- 9.10.6. Business performance
- LIST OF TABLES
- TABLE 01. GLOBAL ERECTILE DYSFUNCTION DRUGS MARKET, BY PRODUCTS, 2022-2032 ($MILLION)
- TABLE 02. ERECTILE DYSFUNCTION DRUGS MARKET FOR SILDENAFIL, BY REGION, 2022-2032 ($MILLION)
- TABLE 03. ERECTILE DYSFUNCTION DRUGS MARKET FOR TADALAFIL, BY REGION, 2022-2032 ($MILLION)
- TABLE 04. ERECTILE DYSFUNCTION DRUGS MARKET FOR UDENAFIL, BY REGION, 2022-2032 ($MILLION)
- TABLE 05. ERECTILE DYSFUNCTION DRUGS MARKET FOR AVANAFIL , BY REGION, 2022-2032 ($MILLION)
- TABLE 06. ERECTILE DYSFUNCTION DRUGS MARKET FOR OTHERS, BY REGION, 2022-2032 ($MILLION)
- TABLE 07. GLOBAL ERECTILE DYSFUNCTION DRUGS MARKET, BY MODE OF ADMINISTRATION , 2022-2032 ($MILLION)
- TABLE 08. ERECTILE DYSFUNCTION DRUGS MARKET FOR ORAL MEDICATION , BY REGION, 2022-2032 ($MILLION)
- TABLE 09. ERECTILE DYSFUNCTION DRUGS MARKET FOR INJECTABLE MEDICATION , BY REGION, 2022-2032 ($MILLION)
- TABLE 10. GLOBAL ERECTILE DYSFUNCTION DRUGS MARKET, BY DISTRIBUTION CHANNELS, 2022-2032 ($MILLION)
- TABLE 11. ERECTILE DYSFUNCTION DRUGS MARKET FOR HOSPITAL PHARMACY, BY REGION, 2022-2032 ($MILLION)
- TABLE 12. ERECTILE DYSFUNCTION DRUGS MARKET FOR RETAIL PHARMACY, BY REGION, 2022-2032 ($MILLION)
- TABLE 13. ERECTILE DYSFUNCTION DRUGS MARKET FOR ONLINE PHARMACY, BY REGION, 2022-2032 ($MILLION)
- TABLE 14. ERECTILE DYSFUNCTION DRUGS MARKET, BY REGION, 2022-2032 ($MILLION)
- TABLE 15. NORTH AMERICA ERECTILE DYSFUNCTION DRUGS MARKET, BY PRODUCTS, 2022-2032 ($MILLION)
- TABLE 16. NORTH AMERICA ERECTILE DYSFUNCTION DRUGS MARKET, BY MODE OF ADMINISTRATION , 2022-2032 ($MILLION)
- TABLE 17. NORTH AMERICA ERECTILE DYSFUNCTION DRUGS MARKET, BY DISTRIBUTION CHANNELS, 2022-2032 ($MILLION)
- TABLE 18. NORTH AMERICA ERECTILE DYSFUNCTION DRUGS MARKET, BY COUNTRY, 2022-2032 ($MILLION)
- TABLE 19. U.S. ERECTILE DYSFUNCTION DRUGS MARKET, BY PRODUCTS, 2022-2032 ($MILLION)
- TABLE 20. U.S. ERECTILE DYSFUNCTION DRUGS MARKET, BY MODE OF ADMINISTRATION , 2022-2032 ($MILLION)
- TABLE 21. U.S. ERECTILE DYSFUNCTION DRUGS MARKET, BY DISTRIBUTION CHANNELS, 2022-2032 ($MILLION)
- TABLE 22. CANADA ERECTILE DYSFUNCTION DRUGS MARKET, BY PRODUCTS, 2022-2032 ($MILLION)
- TABLE 23. CANADA ERECTILE DYSFUNCTION DRUGS MARKET, BY MODE OF ADMINISTRATION , 2022-2032 ($MILLION)
- TABLE 24. CANADA ERECTILE DYSFUNCTION DRUGS MARKET, BY DISTRIBUTION CHANNELS, 2022-2032 ($MILLION)
- TABLE 25. MEXICO ERECTILE DYSFUNCTION DRUGS MARKET, BY PRODUCTS, 2022-2032 ($MILLION)
- TABLE 26. MEXICO ERECTILE DYSFUNCTION DRUGS MARKET, BY MODE OF ADMINISTRATION , 2022-2032 ($MILLION)
- TABLE 27. MEXICO ERECTILE DYSFUNCTION DRUGS MARKET, BY DISTRIBUTION CHANNELS, 2022-2032 ($MILLION)
- TABLE 28. EUROPE ERECTILE DYSFUNCTION DRUGS MARKET, BY PRODUCTS, 2022-2032 ($MILLION)
- TABLE 29. EUROPE ERECTILE DYSFUNCTION DRUGS MARKET, BY MODE OF ADMINISTRATION , 2022-2032 ($MILLION)
- TABLE 30. EUROPE ERECTILE DYSFUNCTION DRUGS MARKET, BY DISTRIBUTION CHANNELS, 2022-2032 ($MILLION)
- TABLE 31. EUROPE ERECTILE DYSFUNCTION DRUGS MARKET, BY COUNTRY, 2022-2032 ($MILLION)
- TABLE 32. GERMANY ERECTILE DYSFUNCTION DRUGS MARKET, BY PRODUCTS, 2022-2032 ($MILLION)
- TABLE 33. GERMANY ERECTILE DYSFUNCTION DRUGS MARKET, BY MODE OF ADMINISTRATION , 2022-2032 ($MILLION)
- TABLE 34. GERMANY ERECTILE DYSFUNCTION DRUGS MARKET, BY DISTRIBUTION CHANNELS, 2022-2032 ($MILLION)
- TABLE 35. FRANCE ERECTILE DYSFUNCTION DRUGS MARKET, BY PRODUCTS, 2022-2032 ($MILLION)
- TABLE 36. FRANCE ERECTILE DYSFUNCTION DRUGS MARKET, BY MODE OF ADMINISTRATION , 2022-2032 ($MILLION)
- TABLE 37. FRANCE ERECTILE DYSFUNCTION DRUGS MARKET, BY DISTRIBUTION CHANNELS, 2022-2032 ($MILLION)
- TABLE 38. UK ERECTILE DYSFUNCTION DRUGS MARKET, BY PRODUCTS, 2022-2032 ($MILLION)
- TABLE 39. UK ERECTILE DYSFUNCTION DRUGS MARKET, BY MODE OF ADMINISTRATION , 2022-2032 ($MILLION)
- TABLE 40. UK ERECTILE DYSFUNCTION DRUGS MARKET, BY DISTRIBUTION CHANNELS, 2022-2032 ($MILLION)
- TABLE 41. ITALY ERECTILE DYSFUNCTION DRUGS MARKET, BY PRODUCTS, 2022-2032 ($MILLION)
- TABLE 42. ITALY ERECTILE DYSFUNCTION DRUGS MARKET, BY MODE OF ADMINISTRATION , 2022-2032 ($MILLION)
- TABLE 43. ITALY ERECTILE DYSFUNCTION DRUGS MARKET, BY DISTRIBUTION CHANNELS, 2022-2032 ($MILLION)
- TABLE 44. SPAIN ERECTILE DYSFUNCTION DRUGS MARKET, BY PRODUCTS, 2022-2032 ($MILLION)
- TABLE 45. SPAIN ERECTILE DYSFUNCTION DRUGS MARKET, BY MODE OF ADMINISTRATION , 2022-2032 ($MILLION)
- TABLE 46. SPAIN ERECTILE DYSFUNCTION DRUGS MARKET, BY DISTRIBUTION CHANNELS, 2022-2032 ($MILLION)
- TABLE 47. REST OF EUROPE ERECTILE DYSFUNCTION DRUGS MARKET, BY PRODUCTS, 2022-2032 ($MILLION)
- TABLE 48. REST OF EUROPE ERECTILE DYSFUNCTION DRUGS MARKET, BY MODE OF ADMINISTRATION , 2022-2032 ($MILLION)
- TABLE 49. REST OF EUROPE ERECTILE DYSFUNCTION DRUGS MARKET, BY DISTRIBUTION CHANNELS, 2022-2032 ($MILLION)
- TABLE 50. ASIA-PACIFIC ERECTILE DYSFUNCTION DRUGS MARKET, BY PRODUCTS, 2022-2032 ($MILLION)
- TABLE 51. ASIA-PACIFIC ERECTILE DYSFUNCTION DRUGS MARKET, BY MODE OF ADMINISTRATION , 2022-2032 ($MILLION)
- TABLE 52. ASIA-PACIFIC ERECTILE DYSFUNCTION DRUGS MARKET, BY DISTRIBUTION CHANNELS, 2022-2032 ($MILLION)
- TABLE 53. ASIA-PACIFIC ERECTILE DYSFUNCTION DRUGS MARKET, BY COUNTRY, 2022-2032 ($MILLION)
- TABLE 54. JAPAN ERECTILE DYSFUNCTION DRUGS MARKET, BY PRODUCTS, 2022-2032 ($MILLION)
- TABLE 55. JAPAN ERECTILE DYSFUNCTION DRUGS MARKET, BY MODE OF ADMINISTRATION , 2022-2032 ($MILLION)
- TABLE 56. JAPAN ERECTILE DYSFUNCTION DRUGS MARKET, BY DISTRIBUTION CHANNELS, 2022-2032 ($MILLION)
- TABLE 57. CHINA ERECTILE DYSFUNCTION DRUGS MARKET, BY PRODUCTS, 2022-2032 ($MILLION)
- TABLE 58. CHINA ERECTILE DYSFUNCTION DRUGS MARKET, BY MODE OF ADMINISTRATION , 2022-2032 ($MILLION)
- TABLE 59. CHINA ERECTILE DYSFUNCTION DRUGS MARKET, BY DISTRIBUTION CHANNELS, 2022-2032 ($MILLION)
- TABLE 60. INDIA ERECTILE DYSFUNCTION DRUGS MARKET, BY PRODUCTS, 2022-2032 ($MILLION)
- TABLE 61. INDIA ERECTILE DYSFUNCTION DRUGS MARKET, BY MODE OF ADMINISTRATION , 2022-2032 ($MILLION)
- TABLE 62. INDIA ERECTILE DYSFUNCTION DRUGS MARKET, BY DISTRIBUTION CHANNELS, 2022-2032 ($MILLION)
- TABLE 63. AUSTRALIA ERECTILE DYSFUNCTION DRUGS MARKET, BY PRODUCTS, 2022-2032 ($MILLION)
- TABLE 64. AUSTRALIA ERECTILE DYSFUNCTION DRUGS MARKET, BY MODE OF ADMINISTRATION , 2022-2032 ($MILLION)
- TABLE 65. AUSTRALIA ERECTILE DYSFUNCTION DRUGS MARKET, BY DISTRIBUTION CHANNELS, 2022-2032 ($MILLION)
- TABLE 66. SOUTH KOREA ERECTILE DYSFUNCTION DRUGS MARKET, BY PRODUCTS, 2022-2032 ($MILLION)
- TABLE 67. SOUTH KOREA ERECTILE DYSFUNCTION DRUGS MARKET, BY MODE OF ADMINISTRATION , 2022-2032 ($MILLION)
- TABLE 68. SOUTH KOREA ERECTILE DYSFUNCTION DRUGS MARKET, BY DISTRIBUTION CHANNELS, 2022-2032 ($MILLION)
- TABLE 69. REST OF ASIA-PACIFIC ERECTILE DYSFUNCTION DRUGS MARKET, BY PRODUCTS, 2022-2032 ($MILLION)
- TABLE 70. REST OF ASIA-PACIFIC ERECTILE DYSFUNCTION DRUGS MARKET, BY MODE OF ADMINISTRATION , 2022-2032 ($MILLION)
- TABLE 71. REST OF ASIA-PACIFIC ERECTILE DYSFUNCTION DRUGS MARKET, BY DISTRIBUTION CHANNELS, 2022-2032 ($MILLION)
- TABLE 72. LAMEA ERECTILE DYSFUNCTION DRUGS MARKET, BY PRODUCTS, 2022-2032 ($MILLION)
- TABLE 73. LAMEA ERECTILE DYSFUNCTION DRUGS MARKET, BY MODE OF ADMINISTRATION , 2022-2032 ($MILLION)
- TABLE 74. LAMEA ERECTILE DYSFUNCTION DRUGS MARKET, BY DISTRIBUTION CHANNELS, 2022-2032 ($MILLION)
- TABLE 75. LAMEA ERECTILE DYSFUNCTION DRUGS MARKET, BY COUNTRY, 2022-2032 ($MILLION)
- TABLE 76. BRAZIL ERECTILE DYSFUNCTION DRUGS MARKET, BY PRODUCTS, 2022-2032 ($MILLION)
- TABLE 77. BRAZIL ERECTILE DYSFUNCTION DRUGS MARKET, BY MODE OF ADMINISTRATION , 2022-2032 ($MILLION)
- TABLE 78. BRAZIL ERECTILE DYSFUNCTION DRUGS MARKET, BY DISTRIBUTION CHANNELS, 2022-2032 ($MILLION)
- TABLE 79. SAUDI ARABIA ERECTILE DYSFUNCTION DRUGS MARKET, BY PRODUCTS, 2022-2032 ($MILLION)
- TABLE 80. SAUDI ARABIA ERECTILE DYSFUNCTION DRUGS MARKET, BY MODE OF ADMINISTRATION , 2022-2032 ($MILLION)
- TABLE 81. SAUDI ARABIA ERECTILE DYSFUNCTION DRUGS MARKET, BY DISTRIBUTION CHANNELS, 2022-2032 ($MILLION)
- TABLE 82. SOUTH AFRICA ERECTILE DYSFUNCTION DRUGS MARKET, BY PRODUCTS, 2022-2032 ($MILLION)
- TABLE 83. SOUTH AFRICA ERECTILE DYSFUNCTION DRUGS MARKET, BY MODE OF ADMINISTRATION , 2022-2032 ($MILLION)
- TABLE 84. SOUTH AFRICA ERECTILE DYSFUNCTION DRUGS MARKET, BY DISTRIBUTION CHANNELS, 2022-2032 ($MILLION)
- TABLE 85. REST OF LAMEA ERECTILE DYSFUNCTION DRUGS MARKET, BY PRODUCTS, 2022-2032 ($MILLION)
- TABLE 86. REST OF LAMEA ERECTILE DYSFUNCTION DRUGS MARKET, BY MODE OF ADMINISTRATION , 2022-2032 ($MILLION)
- TABLE 87. REST OF LAMEA ERECTILE DYSFUNCTION DRUGS MARKET, BY DISTRIBUTION CHANNELS, 2022-2032 ($MILLION)
- TABLE 88. PFIZER INC.: KEY EXECUTIVES
- TABLE 89. PFIZER INC.: COMPANY SNAPSHOT
- TABLE 90. PFIZER INC.: PRODUCT SEGMENTS
- TABLE 91. PFIZER INC.: PRODUCT PORTFOLIO
- TABLE 92. PFIZER INC.: KEY STRATERGIES
- TABLE 93. ELI LILLY AND COMPANY: KEY EXECUTIVES
- TABLE 94. ELI LILLY AND COMPANY: COMPANY SNAPSHOT
- TABLE 95. ELI LILLY AND COMPANY: PRODUCT SEGMENTS
- TABLE 96. ELI LILLY AND COMPANY: PRODUCT PORTFOLIO
- TABLE 97. TEVA PHARMACEUTICAL INDUSTRIES LTD.: KEY EXECUTIVES
- TABLE 98. TEVA PHARMACEUTICAL INDUSTRIES LTD.: COMPANY SNAPSHOT
- TABLE 99. TEVA PHARMACEUTICAL INDUSTRIES LTD.: PRODUCT SEGMENTS
- TABLE 100. TEVA PHARMACEUTICAL INDUSTRIES LTD.: PRODUCT PORTFOLIO
- TABLE 101. SANOFI: KEY EXECUTIVES
- TABLE 102. SANOFI: COMPANY SNAPSHOT
- TABLE 103. SANOFI: PRODUCT SEGMENTS
- TABLE 104. SANOFI: PRODUCT PORTFOLIO
- TABLE 105. BAYER AG: KEY EXECUTIVES
- TABLE 106. BAYER AG: COMPANY SNAPSHOT
- TABLE 107. BAYER AG: PRODUCT SEGMENTS
- TABLE 108. BAYER AG: PRODUCT PORTFOLIO
- TABLE 109. VIVUS LLC.: KEY EXECUTIVES
- TABLE 110. VIVUS LLC.: COMPANY SNAPSHOT
- TABLE 111. VIVUS LLC.: PRODUCT SEGMENTS
- TABLE 112. VIVUS LLC.: SERVICE SEGMENTS
- TABLE 113. VIVUS LLC.: PRODUCT PORTFOLIO
- TABLE 114. ADAMED: KEY EXECUTIVES
- TABLE 115. ADAMED: COMPANY SNAPSHOT
- TABLE 116. ADAMED: PRODUCT SEGMENTS
- TABLE 117. ADAMED: PRODUCT PORTFOLIO
- TABLE 118. GLENMARK PHARMACEUTICALS LIMITED: KEY EXECUTIVES
- TABLE 119. GLENMARK PHARMACEUTICALS LIMITED: COMPANY SNAPSHOT
- TABLE 120. GLENMARK PHARMACEUTICALS LIMITED: PRODUCT SEGMENTS
- TABLE 121. GLENMARK PHARMACEUTICALS LIMITED: PRODUCT PORTFOLIO
- TABLE 122. GLENMARK PHARMACEUTICALS LIMITED: KEY STRATERGIES
- TABLE 123. CIPLA LTD: KEY EXECUTIVES
- TABLE 124. CIPLA LTD: COMPANY SNAPSHOT
- TABLE 125. CIPLA LTD: PRODUCT SEGMENTS
- TABLE 126. CIPLA LTD: PRODUCT PORTFOLIO
- TABLE 127. SUN PHARMACEUTICAL INDUSTRIES LIMITED: KEY EXECUTIVES
- TABLE 128. SUN PHARMACEUTICAL INDUSTRIES LIMITED: COMPANY SNAPSHOT
- TABLE 129. SUN PHARMACEUTICAL INDUSTRIES LIMITED: PRODUCT SEGMENTS
- TABLE 130. SUN PHARMACEUTICAL INDUSTRIES LIMITED: PRODUCT PORTFOLIO
- LIST OF FIGURES
- FIGURE 01. ERECTILE DYSFUNCTION DRUGS MARKET, 2022-2032
- FIGURE 02. SEGMENTATION OF ERECTILE DYSFUNCTION DRUGS MARKET, 2022-2032
- FIGURE 03. TOP INVESTMENT POCKETS IN ERECTILE DYSFUNCTION DRUGS MARKET (2023-2032)
- FIGURE 04. MODERATE BARGAINING POWER OF SUPPLIERS
- FIGURE 05. MODERATE BARGAINING POWER OF BUYERS
- FIGURE 06. MODERATE THREAT OF SUBSTITUTES
- FIGURE 07. LOW THREAT OF NEW ENTRANTS
- FIGURE 08. MODERATE INTENSITY OF RIVALRY
- FIGURE 09. DRIVERS, RESTRAINTS AND OPPORTUNITIES: GLOBALERECTILE DYSFUNCTION DRUGS MARKET
- FIGURE 10. ERECTILE DYSFUNCTION DRUGS MARKET, BY PRODUCTS, 2022(%)
- FIGURE 11. COMPARATIVE SHARE ANALYSIS OF ERECTILE DYSFUNCTION DRUGS MARKET FOR SILDENAFIL, BY COUNTRY 2022 AND 2032(%)
- FIGURE 12. COMPARATIVE SHARE ANALYSIS OF ERECTILE DYSFUNCTION DRUGS MARKET FOR TADALAFIL, BY COUNTRY 2022 AND 2032(%)
- FIGURE 13. COMPARATIVE SHARE ANALYSIS OF ERECTILE DYSFUNCTION DRUGS MARKET FOR UDENAFIL, BY COUNTRY 2022 AND 2032(%)
- FIGURE 14. COMPARATIVE SHARE ANALYSIS OF ERECTILE DYSFUNCTION DRUGS MARKET FOR AVANAFIL , BY COUNTRY 2022 AND 2032(%)
- FIGURE 15. COMPARATIVE SHARE ANALYSIS OF ERECTILE DYSFUNCTION DRUGS MARKET FOR OTHERS, BY COUNTRY 2022 AND 2032(%)
- FIGURE 16. ERECTILE DYSFUNCTION DRUGS MARKET, BY MODE OF ADMINISTRATION , 2022(%)
- FIGURE 17. COMPARATIVE SHARE ANALYSIS OF ERECTILE DYSFUNCTION DRUGS MARKET FOR ORAL MEDICATION , BY COUNTRY 2022 AND 2032(%)
- FIGURE 18. COMPARATIVE SHARE ANALYSIS OF ERECTILE DYSFUNCTION DRUGS MARKET FOR INJECTABLE MEDICATION , BY COUNTRY 2022 AND 2032(%)
- FIGURE 19. ERECTILE DYSFUNCTION DRUGS MARKET, BY DISTRIBUTION CHANNELS, 2022(%)
- FIGURE 20. COMPARATIVE SHARE ANALYSIS OF ERECTILE DYSFUNCTION DRUGS MARKET FOR HOSPITAL PHARMACY, BY COUNTRY 2022 AND 2032(%)
- FIGURE 21. COMPARATIVE SHARE ANALYSIS OF ERECTILE DYSFUNCTION DRUGS MARKET FOR RETAIL PHARMACY, BY COUNTRY 2022 AND 2032(%)
- FIGURE 22. COMPARATIVE SHARE ANALYSIS OF ERECTILE DYSFUNCTION DRUGS MARKET FOR ONLINE PHARMACY, BY COUNTRY 2022 AND 2032(%)
- FIGURE 23. ERECTILE DYSFUNCTION DRUGS MARKET BY REGION, 2022
- FIGURE 24. U.S. ERECTILE DYSFUNCTION DRUGS MARKET, 2022-2032 ($MILLION)
- FIGURE 25. CANADA ERECTILE DYSFUNCTION DRUGS MARKET, 2022-2032 ($MILLION)
- FIGURE 26. MEXICO ERECTILE DYSFUNCTION DRUGS MARKET, 2022-2032 ($MILLION)
- FIGURE 27. GERMANY ERECTILE DYSFUNCTION DRUGS MARKET, 2022-2032 ($MILLION)
- FIGURE 28. FRANCE ERECTILE DYSFUNCTION DRUGS MARKET, 2022-2032 ($MILLION)
- FIGURE 29. UK ERECTILE DYSFUNCTION DRUGS MARKET, 2022-2032 ($MILLION)
- FIGURE 30. ITALY ERECTILE DYSFUNCTION DRUGS MARKET, 2022-2032 ($MILLION)
- FIGURE 31. SPAIN ERECTILE DYSFUNCTION DRUGS MARKET, 2022-2032 ($MILLION)
- FIGURE 32. REST OF EUROPE ERECTILE DYSFUNCTION DRUGS MARKET, 2022-2032 ($MILLION)
- FIGURE 33. JAPAN ERECTILE DYSFUNCTION DRUGS MARKET, 2022-2032 ($MILLION)
- FIGURE 34. CHINA ERECTILE DYSFUNCTION DRUGS MARKET, 2022-2032 ($MILLION)
- FIGURE 35. INDIA ERECTILE DYSFUNCTION DRUGS MARKET, 2022-2032 ($MILLION)
- FIGURE 36. AUSTRALIA ERECTILE DYSFUNCTION DRUGS MARKET, 2022-2032 ($MILLION)
- FIGURE 37. SOUTH KOREA ERECTILE DYSFUNCTION DRUGS MARKET, 2022-2032 ($MILLION)
- FIGURE 38. REST OF ASIA-PACIFIC ERECTILE DYSFUNCTION DRUGS MARKET, 2022-2032 ($MILLION)
- FIGURE 39. BRAZIL ERECTILE DYSFUNCTION DRUGS MARKET, 2022-2032 ($MILLION)
- FIGURE 40. SAUDI ARABIA ERECTILE DYSFUNCTION DRUGS MARKET, 2022-2032 ($MILLION)
- FIGURE 41. SOUTH AFRICA ERECTILE DYSFUNCTION DRUGS MARKET, 2022-2032 ($MILLION)
- FIGURE 42. REST OF LAMEA ERECTILE DYSFUNCTION DRUGS MARKET, 2022-2032 ($MILLION)
- FIGURE 43. TOP WINNING STRATEGIES, BY YEAR
- FIGURE 44. TOP WINNING STRATEGIES, BY DEVELOPMENT
- FIGURE 45. TOP WINNING STRATEGIES, BY COMPANY
- FIGURE 46. PRODUCT MAPPING OF TOP 10 PLAYERS
- FIGURE 47. COMPETITIVE DASHBOARD
- FIGURE 48. COMPETITIVE HEATMAP: ERECTILE DYSFUNCTION DRUGS MARKET
- FIGURE 49. TOP PLAYER POSITIONING, 2022
- FIGURE 50. PFIZER INC.: NET REVENUE, 2020-2022 ($MILLION)
- FIGURE 51. PFIZER INC.: REVENUE SHARE BY SEGMENT, 2022 (%)
- FIGURE 52. PFIZER INC.: REVENUE SHARE BY REGION, 2022 (%)
- FIGURE 53. ELI LILLY AND COMPANY: NET REVENUE, 2020-2022 ($MILLION)
- FIGURE 54. ELI LILLY AND COMPANY: REVENUE SHARE BY REGION, 2022 (%)
- FIGURE 55. TEVA PHARMACEUTICAL INDUSTRIES LTD.: NET REVENUE, 2020-2022 ($MILLION)
- FIGURE 56. TEVA PHARMACEUTICAL INDUSTRIES LTD.: REVENUE SHARE BY REGION, 2022 (%)
- FIGURE 57. SANOFI: NET SALES, 2020-2022 ($MILLION)
- FIGURE 58. SANOFI: REVENUE SHARE BY SEGMENT, 2022 (%)
- FIGURE 59. SANOFI: REVENUE SHARE BY REGION, 2022 (%)
- FIGURE 60. BAYER AG: NET SALES, 2020-2022 ($MILLION)
- FIGURE 61. BAYER AG: REVENUE SHARE BY SEGMENT, 2022 (%)
- FIGURE 62. BAYER AG: REVENUE SHARE BY REGION, 2022 (%)
- FIGURE 63. GLENMARK PHARMACEUTICALS LIMITED: NET SALES, 2020-2022 ($MILLION)
- FIGURE 64. GLENMARK PHARMACEUTICALS LIMITED: REVENUE SHARE BY REGION, 2022 (%)
- FIGURE 65. CIPLA LTD: SALES REVENUE, 2020-2022 ($MILLION)
- FIGURE 66. CIPLA LTD: REVENUE SHARE BY SEGMENT, 2022 (%)
- FIGURE 67. CIPLA LTD: REVENUE SHARE BY REGION, 2022 (%)
- FIGURE 68. SUN PHARMACEUTICAL INDUSTRIES LIMITED: SALES REVENUE, 2020-2022 ($MILLION)
- FIGURE 69. SUN PHARMACEUTICAL INDUSTRIES LIMITED: REVENUE SHARE BY REGION, 2022 (%)
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
